What Is CagriSema? The Amylin + GLP-1 Combination Explained
Research & educational use only. This content is not medical advice. Consult a qualified healthcare professional before using any peptide compound.
CagriSema is a next-generation weight-loss combination that pairs two different peptides: cagrilintide, a long-acting amylin analog, and semaglutide, the well-known GLP-1 agonist. The idea is that hitting two separate appetite pathways at once produces more weight loss than either alone. It is one of the most-discussed metabolic candidates of 2026, alongside retatrutide. This guide explains what CagriSema is, how it differs from a triple agonist, and what the trials show. It is for research and educational purposes only, is not medical advice, and PeptidesHub does not sell peptides.
What is CagriSema?
CagriSema is a combination of two molecules, not a single new peptide. It joins cagrilintide (an amylin analog, internal code AM833) with semaglutide (a GLP-1 receptor agonist already approved as Ozempic and Wegovy). Both are developed by Novo Nordisk, and the combination is being studied as a once-weekly injectable for obesity and type 2 diabetes.
How does amylin work, and why combine it with GLP-1?
Amylin is a hormone co-secreted with insulin from the pancreas that acts on the brain to promote satiety — a different appetite pathway from GLP-1. Cagrilintide is a long-acting synthetic version of it. The rationale for CagriSema is complementary mechanisms: GLP-1 and amylin reduce appetite through partly separate routes, so combining them may add up to more weight loss than either alone.
What do the CagriSema trials show?
CagriSema has been studied in the phase 3 REDEFINE program. Reported results put weight loss in the low-to-mid 20% range over roughly a year and a half — strong, and broadly competitive with the best dual agonists, though the headline numbers came in somewhat below early expectations and below what retatrutide has reported. As always, cross-trial comparisons are not head-to-head, and the full data picture is still developing in 2026.
CagriSema vs retatrutide: what’s the difference?
They are two different strategies for the same goal. CagriSema is a two-drug combination (amylin analog + GLP-1). Retatrutide is a single molecule that activates three receptors (GIP, GLP-1, and glucagon). Both aim to push weight loss beyond what today’s GLP-1 drugs achieve, but one does it by combining peptides and the other by engineering one peptide to hit more targets.
Is CagriSema FDA approved or available?
As of 2026, CagriSema is in late-stage clinical development and is not yet an FDA-approved, finished prescription product. Its individual component semaglutide is approved, but the CagriSema combination is not. Any "CagriSema" sold online is unapproved research-chemical material — its identity, dosing, and purity are not guaranteed.
What about sourcing the components?
Because no approved combination product exists, gray-market versions are unregulated. If you are researching sources at all, third-party lab testing is essential — demand a batch-specific certificate of analysis for each peptide, and check the ranked sellers directory and warnings feed. None of this is a recommendation to obtain or use CagriSema or its components.